Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APTO-253 in Relapsed/Refractory AML or High-Risk MDS
NCT02267863Phase 1Terminated
- Sponsor
- Aptose Biosciences Inc.
- Start
- Oct 2014
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of APTO-253 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Aptose Biosciences Inc. Primary endpoints: Incidence of treatment-emergent adverse events, Maximum Tolerated Dose and 1 more. Started Oct 2014; status: terminated.
02
Drugs
APTO-253
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02267863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02267863.